Among the 208 cases, according to biological tumor subtypes, 33 (15.9%) had triple-negative breast cancer, 99 (47.6%) had HER2-positive disease, and the remaining 76 (36.5%) had luminal disease. Here, ERBB2 is linked to triple-negative breast carcinoma.